• Health Catalyst Invests In healthfinch

    To kick off the third quarter, Health Catalyst has announced its second acquisition of 2020. On July 9, the company announced it acquired healthfinch, Inc. for roughly $40 million. healthfinch provides a workflow integration engine delivering insights and analytics into EMR workflows to automate physicians’ ability to close patient care gaps in... Read More »
  • Second Quarter Healthcare M&A Activity Drops

    The decline in second quarter healthcare M&A probably won’t surprise many of our readers. The second quarter was the first full quarter of healthcare M&A in the shadow of the COVID-19 pandemic, and deal making took a hit as a result, as shown in results from our DSO database. Compared with Q1:20, Q2:20 dropped 20%, with 322 transactions... Read More »
  • Sanofi Inks New Licensing Deal

    Just weeks following its agreement with Translate Bio (NASDAQ: TBIO) for COVID-19 vaccine development, Sanofi (NYSE: SNY) has a new agreement with Kymera Therapeutics Inc. Sanofi and Kymera are signing a multi-program collaboration to develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with... Read More »
  • Summit BHC Expands Into West Virginia

    Private equity-backed Summit BHC has announced a new acquisition in West Virginia. The behavioral health treatment company added Highland Hospital to its network for an undisclosed sum. Meridian Behavioral Health Systems, LLC is selling Highland Hospital, an inpatient psychiatric facility (131 beds) with 24 beds dedicated to psychiatric... Read More »
  • Health Care M&A Deals, July 10, 2020

    The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week based on... Read More »

DaVita Divests Seven Dialysis Clinics

DaVita Inc. (NYSE: DVA) isn’t usually on the sell-side of dialysis deals. In fact, the company hasn’t announced a sale from its renal care division in the past five years. But in late March, the Federal Trade Commission ordered DaVita to divest its ownership in seven dialysis clinics. That order was part of a settlement resolving charges that DaVita’s $358 million acquisition of Renal Ventures Management, LLC would be anticompetitive. At the time of that deal’s announcement in August 2015, Renal Ventures operated 36 dialysis clinics in six states. The company’s two divisions, Multispecialty Physician Partners and Physician Venture Partners, operated infusion... Read More »

Two Deals for Renal Care Providers

Consolidation is still possible in the kidney-care sector, even though Fresenius Medical Care (NYSE: FMS) and DaVita HealthCare Partners (NYSE: DVA) appear to have about 90% of the U.S. market. Last week, DaVita announced its $415 million acquisition of Renal Ventures Management, LLC, a network of 36 dialysis clinics in six states, with headquarters in Lakewood, Colorado. RVM’s two physician divisions, Multispecialty Physician Partners and Physician Venture Partners were part of the deal. The second acquisition came from a much smaller player, privately held U.S. Renal Care, Inc. of Plano, Texas. The target was DSI Renal, owned by Frazier Healthcare and New Enterprise Associates, which... Read More »